. 2021 Jun 4;11:11882. doi: 10.1038/s41598-021-91449-z

Table 3.

Univariate and multivariate analyses of factors associated with overall survival.

Factor		Number of deaths	Univariate analysis	Multivariate analysis	Hazard ratio
Factor		Number of deaths	p-value	p-value	(95% CI)
Sex	F	4/9	0.3	NE	–
Sex	M	32/51	0.3	NE	–
Age (years)	< 66	16/28	0.6	NE	–
Age (years)	≥ 66	20/32	0.6	NE	–
T Stage	X, 1–2	10/22	0.2	NE	–
T Stage	3–4	26/38	0.2	NE	–
N Stage	0–1	3/8	0.4	NE	–
N Stage	2–3	33/52	0.4	NE	–
Clinical stage	IIIA	6/16	0.3	NE	–
	IIIB	22/32
	IIIC	8/12
Histology	Adenocarcinoma	16/26	0.5	NE	–
Histology	Others	20/34	0.5	NE	–
Smoking history^a	Never/former	21/36	0.9	NE	–
Smoking history^a	Current	13/22	0.9	NE	–
ECOG-PS^a	0	8/21	0.004	0.011	2.91
ECOG-PS^a	1	25/36	0.004	0.011	(1.28–6.64)
Laterality	Right	17/31	0.5	NE	–
Laterality	Left	18/26	0.5	NE	–
Lobe	Upper/middle	28/49	0.2	NE	–
Lobe	Lower	8/11	0.2	NE	–
FEV1 (l)^a	< 2.2	17/29	0.2	NE	–
FEV1 (l)^a	≥ 2.2	13/22	0.2	NE	–
Chemotherapy	Standard	29/49	0.5	NE	–
Chemotherapy	Reduced	7/11	0.5	NE	–
BMI^a	F: < 17, M: < 25	28/41	0.03	NE	–
BMI^a	F: ≥ 17, M: ≥ 25	7/18	0.03	NE	–
SMI	F: < 24, M: < 43	17/22	0.01	0.02	2.36
SMI	F: ≥ 24, M: ≥ 43	19/38	0.01	0.02	(1.15–4.85)
PMI	F: < 4.7, M: < 7.3	31/52	0.4	NE	–
PMI	F: ≥ 4.7, M: ≥ 7.3	5/8	0.4	NE	–
MA	F: < 9, M: < 36	15/24	> 0.99	NE	–
MA	F: ≥ 9, M: ≥ 36	21/36	> 0.99	NE	–
VAI	F: < 97, M: < 40	28/42	0.1	NE	–
VAI	F: ≥ 97, M: ≥ 40	8/18	0.1	NE	–
SAI	F: < 127, M: < 28	23/34	0.09	NE	–
SAI	F: ≥ 127, M: ≥ 28	13/26	0.09	NE	–
VSR	F: < 0.8, M: < 0.6	8/19	0.1	NE	–
VSR	F: ≥ 0.8, M: ≥ 0.6	28/41	0.1	NE	–

NE not entered, ECOG-PS Eastern Cooperative Oncology Group performance status, FEV1 forced expiratory volume in 1 s, BMI body mass index, MA mean muscle attenuation, SMI skeletal mass muscle index, PMI psoas muscle index, VAI visceral adiposity index, SAI subcutaneous adiposity index, VSR visceral-to-subcutaneous fat ratio, CI confidence interval.

^aThese variables have missing values.